This Is MS Multiple Sclerosis Community: Knowledge & Support

Dignan has already highlighted the research about this supplement. Here is another summary of the research:

http://www.medicalnewstoday.com/medical ... wsid=34218


By coincidence I found a jar in my bathroom cabinet so I have started taking them. Has anyone who has taken them noticed any improvements?


Ian

Dignan,

Came across the following company who are developing drugs for diseases caused by viruses (including MS). They have one treatment for MS in development. Not sure if it is included in your list as the company is part owned by Nutra Pharma

Ian

<shortened url>

Does anyone participate a clinical study with CNT 1275 (CENTOCOR). I´m patient from Czech republic and we are only free persons ivolved in this study in my MS centrum, where I´m cured. Please anybody, who has inspierence with this, answer me.

Can I recognize, that I use placebo?

Any opinions and/or data on which of these drugs in the pipeline shows the most promise for becoming a viable and effective treatment in the next 2-3 years? Tovaxin, Neurovax, FTY720 seem to have the most "buzz" at this point. $12,000 per year for a possible 30% reduction in relapse rate just doesn't cut it.

An article on neurovax

http://c.moreover.com/click/here.pl?j417957389&w=464753

http://www.nationalmssociety.org/Research-2005Nov4.asp

However bad you think you have it some poor bastard has it worse. Here is an article from the Boston Cure Project about two MS horror stories where Rituximab helped.

'B' cells seem to be the culprits in these cases (not sure if 'T' cells played a role).



http://www.bostoncure.org:8080/article. ... =nocomment

Good news for MBP8298 Phase II/III trial...



Data Safety Monitoring Board gives positive review for BioMS Medical's pivotal MS trial

October 27 - CNW - BioMS Medical Corp., a leading developer in the treatment of multiple sclerosis (MS), announced that following the second meeting of its independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple ...

This is my first post and I don't really have a clue what I am doing! I came across this "lead-in" article on the "news for the day", i.e., current, New England Journal website. It costs $29.95 to read the entire article and I really don't want to make the investment. Perhaps some of you know what this means:

Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis

To the Editor: According to the established definition of ...

http://c.moreover.com/click/here.pl?j412355639&w=464753